Ignite Creation Date:
2025-12-25 @ 3:39 AM
Ignite Modification Date:
2026-02-03 @ 6:45 AM
Study NCT ID:
NCT07279402
Status:
RECRUITING
Last Update Posted:
2025-12-12
First Post:
2025-12-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Sponsor:
Antalya Training and Research Hospital
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
MON1068.1.82
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |